Nautilus Biotechnology, Inc.
NAUT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.24 | 0.20 | 0.23 | -0.39 |
| FCF Yield | -10.74% | -15.03% | -13.16% | -6.89% |
| EV / EBITDA | -9.18 | -5.12 | -6.02 | -11.62 |
| Quality | ||||
| ROIC | -7.89% | -8.17% | -8.42% | -8.35% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 50.00% |
| Cash Conversion Ratio | 0.81 | 0.89 | 0.84 | 0.81 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 16.69% | 2.90% | 2.79% | -5.36% |
| Safety | ||||
| Net Debt / EBITDA | -0.26 | 0.38 | 0.23 | -0.15 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -24.67 | -53.68 | -46.58 | -18.51 |